The addressable patient population in the US could increase by 4.5 million if new trial is successful.
Amgen Inc.'s plan to run a new cardiovascular outcomes study of its PCSK9 inhibitor Repatha (evolocumab) in high-risk patients who haven't had a cardiovascular event yet has the potential to greatly broaden the target population for the drug.
The VESALIUS-CV trial will be done in collaboration with the Brigham and Women's Hospital Thrombolysis in Myocardial Infarction (TIMI) Study...
The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Oral RNA splicing modulator has gone into a Phase II/III trial
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.
Wales-based group launches with $140m series A.
